Industry Sponsored Symposia  
Sunday, October 20, 2019

<table>
<thead>
<tr>
<th>Industry Sponsored Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15 – 17:45</td>
</tr>
<tr>
<td>Samsung/Biogen - Enhancing Treatment Success with Anti-TNFs in IBD (Samsung Bioepis/Biogen)</td>
</tr>
<tr>
<td>Chairs: Alessandro Armuzzi, Italy</td>
</tr>
</tbody>
</table>

16:15 - 16:20  
Welcome and Introduction  
Alessandro Armuzzi, Italy

16:20 - 16:55  
Treatment Optimisation in IBD: Optimal Use of Anti-TNF  
Alessandro Armuzzi, Italy  
Yoram Bouhnik, France  
Fraser Cummings, United Kingdom  
Marion Bettey, United Kingdom

16:55 - 17:40  
Utilising Biosimilars in Daily Clinical Practice: Growing Confidence  
Alessandro Armuzzi, Italy  
Yoram Bouhnik, France  
Fraser Cummings, United Kingdom  
Marion Bettey, United Kingdom

17:40 - 17:45  
Wrap-up  
Alessandro Armuzzi, Italy
Industry Sponsored Symposia
Monday, October 21, 2019

Industry Sponsored Symposium
07:00 – 08:00  B5
Vifor – Practical management of anemia after a GI bleed (Vifor Pharma)

07:00 – 07:20
1st clinical case: Acute UGIB in an H. pylori positive patient
Ian Mark Gralnek, Israel

07:20 – 07:40
2nd clinical case: Acute and chronic GIB in patients under antithrombotic therapy
Angel Lanas, Spain

07:40 – 08:00
Interactive Discussion/Q&A with the Panel

Industry Sponsored Symposium
07:00 – 08:00  E2
Abivax - ABX464, a novel anti-inflammatory oral drug candidate based on a new mechanism of action to generate microRNA-124: From bench to bedside
Chairs: William J. Sandborn, United States

07:00 – 07:05
Welcome and opening remarks
William J. Sandborn, United States

07:05 – 07:20
The continued need to develop novel drugs in ulcerative colitis
William J. Sandborn, United States

07:20 – 07:35
Mechanism of action and preclinical assessment of ABX 464
Jamal Tazi, France

07:35 – 07:50
New 12 months maintenance clinical data from the 2a induction and maintenance studies with ABX464 in ulcerative colitis
Jean-Marc Steens, France

07:50 – 08:00
Q&A

Industry Sponsored Symposium
18:00 – 19:30  A2
Pfizer - JAK Inhibition in UC: Practical Guidance for the Clinic
Chairs: Geert D’Haens, Netherlands

18:00 – 18:05
Welcome and Introduction
Geert D’Haens, Netherlands

18:05 – 18:20
The Science of JAK Inhibition: Learnings from Rheumatology
Ernest Choy, United Kingdom

18:20 – 18:50
Tofacitinib in UC: Exploring the Efficacy and Safety Profile
Jonas Halfvarson, Sweden

18:50 – 19:20
Practicalities of Tofacitinib: Dosing and Monitoring in Appropriate Patients
Geert D’Haens, Netherlands

19:20 – 19:30
Panel Discussion with Audience Q&A

Industry Sponsored Symposium
18:00 – 19:30  C3
Takeda – Revisiting treatment success in Crohn’s disease
(Takeda Pharmaceuticals International AG)
Chairs: Silvio Danese, Italy

18:00 – 18:10
Introduction
Silvio Danese, Italy

18:10 – 18:30
Matching variable treatment goals for a variable disease
Remo Panaccione, Canada

18:30 – 18:50
Achieving clinical remission: A sprint and a marathon
Ailsa Hart, United Kingdom

18:50 – 19:10
Mucosal healing and beyond: What is achievable?
Silvio Danese, Italy

19:10 – 19:30
Panel discussion/Q&A

Industry Sponsored Symposium
18:00 – 19:30  F1
FUJIFILM - Advances in Imaging and Endoscopic Techniques
(FUJIFILM Europe GmbH)
Chairs: Alessandro Repici, Italy
Helmut Neumann, Germany

18:00 – 18:10
LCI to increase adenoma detection: a multicenter experience
Silvia Paggi, Italy

18:10 – 18:25
How can I maximize my ADR?
Cesare Hassan, Italy

18:25 – 18:40
Polyp characterization: US Multicenter Study Results
Prateek Sharma, United States

18:40 – 18:55
Novel approach to haemostasis
Pradeep Bhandari, United Kingdom

18:55 – 19:10
Panel discussion/Q&A
18:55 - 19:30
Open discussion

**Industry Sponsored Symposium**
18:00 – 19:30 F2
Janssen - Burning questions in IBD: learnings from emerging drug options and clinical cases

18:00 - 18:10
Welcome and introduction
Severine Vermeire, Belgium

18:10 - 19:20
Burning questions in daily IBD management: learnings from clinical cases
Severine Vermeire, Belgium
Laurent Peyrin-Biroulet, France
Julian Panés, Spain

19:20 - 19:30
Close of meeting
Severine Vermeire, Belgium

**Industry Sponsored Symposium**
18:00 – 19:30 F3
Dr. Falk Pharma - Eosinophilic Esophagitis: Recent Developments in Diagnosis & Treatment (Dr. Falk Pharma GmbH)
Chairs: Arjan Bredenoord, Netherlands
Alex Straumann, Switzerland

18:00 - 18:02
Welcome
Arjan Bredenoord, Netherlands

18:02 - 18:19
Who gets EoE?
Evan S. Dellon, United States

18:19 - 18:36
Challenges in diagnosis and monitoring
Alain Schoepfer, Switzerland

18:36 - 18:53
Topical steroids for everybody?
Stephan Miehlke, Germany

18:53 - 19:10
PPI therapy: chances and limitations
Stephen Attwood, United Kingdom

19:10 - 19:27
Dietary treatment: chances and limitations
Alfredo J. Lucendo, Spain

19:27 - 19:29
Farewell
Alex Straumann, Switzerland
Industry Sponsored Symposia
Tuesday, October 22, 2019

Industry Sponsored Symposium
07:00 – 08:00 A1
 Arena - Expanding horizons: Will oral therapies change the IBD treatment landscape? (Arena Pharmaceuticals)
 Chairs: Stefan Schreiber, Germany

07:00 - 07:05
Welcome and introductions
Stefan Schreiber, Germany

07:05 - 07:20
Navigating the path: The current IBD treatment paradigm
Stefan Schreiber, Germany

07:20 - 07:35
The need to change course? Unmet needs with biologic therapies
Ailsa Hart, United Kingdom

07:35 - 07:50
Exploring new frontiers: Novel and emerging oral therapies in IBD
Laurent Peyrin-Biroulet, France

07:50 - 08:00
Panel Q&A and closing remarks

Industry Sponsored Symposium
07:00 – 08:00 A2
CELLTRION - Pivotal data of subcutaneous infliximab (CELLTRION HEALTHCARE CO., LTD.)
 Chairs: Walter Reinisch, Austria

07:00 - 07:10
Introduction
Walter Reinisch, Austria

07:10 - 07:30
Clinical Evidence of CT-P13 SC Formulation
Shomron Ben-Horin, Israel

07:30 - 07:50
Future with dual formulation of infliximab
Subrata Ghosh, United Kingdom

07:50 - 08:00
Panel Discussion

Industry Sponsored Symposium
07:00 – 08:00 E1
Norgine - Lightening the load of iron deficiency anaemia in inflammatory bowel disease
 Chairs: Silvio Danese, Italy

07:00 - 07:05
Welcome and introduction
Silvio Danese, Italy

07:05 - 07:20
Treating IDA in IBD in theory: evidence and guidelines
Fernando Gomollon Garcia, Spain

07:20 - 07:35
Treating IDA in IBD in practice: real-world experience
Stefanie Howaldt, Germany

07:35 - 07:50
Treating IDA in IBD: could we be doing more?
James Lindsay, United Kingdom

07:50 - 07:58
Audience Q&A

07:58 - 08:00
Summary and close
Silvio Danese, Italy

Industry Sponsored Symposium
18:00 – 19:30 A2
Takeda - Histologic remission in ulcerative colitis: Are we ready? Insights from VARSITY* (Takeda Pharmaceuticals International AG)
 Chairs: Jean-Frederic Colombel, United States

18:00 - 18:10
Introduction: Understanding evolving treatment targets in ulcerative colitis
Jean-Frederic Colombel, United States

18:10 - 18:30
Is histologic healing the ultimate therapeutic goal in ulcerative colitis?
Jean-Frederic Colombel, United States

18:30 - 18:50
What is histologic healing?
Laurent Peyrin-Biroulet, France

18:50 - 19:10
Is histologic healing achievable? Lessons from VARSITY*
Silvio Danese, Italy

19:10 - 19:25
Panel discussion/Q&A

19:25 - 19:30
Conclusions for the practicing physician
Jean-Frederic Colombel, United States

Industry Sponsored Symposium
18:00 – 19:30 C3
AbbVie - Exploring inflammatory pathways in IBD – past, present and future
 Chairs: Remo Panaccione, Canada
18:00 - 18:05
Welcome and introduction
Remo Panaccione, Canada

18:05 - 18:25
Taking root: evolution of IBD management
Remo Panaccione, Canada

18:25 - 18:50
Unfurling the branches of knowledge: targeting the immunopathology of IBD
Raja Atreya, Germany

18:50 - 19:15
Envisioning a blossoming future: expectations for emerging therapies and personalised medicine
Tim Raine, United Kingdom

19:15 - 19:25
Panel discussion and Q&A

19:25 - 19:30
Summary and close
Remo Panaccione, Canada

The programme of industry sponsored symposia is not affiliated with UEG.